PharmaNet andAnapharm Europe end JV

- Last updated on GMT

US CRO PharmaNet and Anapharm Europe have formally ended the bioanalytical services joint venture.

New Jersey-based PharmaNet said the move follows Maria Cruz Caturla’s, Anapharm Europe's majority shareholder, acquisition of its minority interest in the join venture on December 22.

The contract research organisation (CRO) added that both firms will continue to invest in the respective bioanalystical portfolios and will continue to work together on exsiting projects to provide coordinated support as is required.

Anapharm Europe, which is headquartered in Spain, provides bioanalysis services to drug and biopharmaceutical firms at its laboratory in Barcelona.

Related news

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers